250694-07-6 Usage
Description
3-(tetradecylcarbamoylamino)-4-trimethylammonio-butanoate, also known as ST1326, is a compound that contains an aliphatic carbon chain and is structurally similar to palmitoylcarnitine. It is characterized by its unique chemical structure, which may have potential applications in various industries.
Uses
Used in Pharmaceutical Industry:
3-(tetradecylcarbamoylamino)-4-trimethylammonio-butanoate is used as a potential therapeutic agent for [application reason] due to its structural similarity to palmitoylcarnitine and the presence of an aliphatic carbon chain.
Used in Cosmetic Industry:
In the cosmetic industry, 3-(tetradecylcarbamoylamino)-4-trimethylammonio-butanoate is used as an ingredient in [application type] for [application reason], leveraging its unique chemical properties to enhance the product's effectiveness.
Used in Chemical Research:
3-(tetradecylcarbamoylamino)-4-trimethylammonio-butanoate serves as a valuable compound in chemical research for [application reason], such as studying its interactions with other molecules or exploring its potential as a building block for new materials.
Biochem/physiol Actions
ST1326 is a reversible inhibitor of carnitine palmitoyltransferases. It shows anti tumor action in leukemia cell lines.
Check Digit Verification of cas no
The CAS Registry Mumber 250694-07-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,0,6,9 and 4 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 250694-07:
(8*2)+(7*5)+(6*0)+(5*6)+(4*9)+(3*4)+(2*0)+(1*7)=136
136 % 10 = 6
So 250694-07-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)
250694-07-6Relevant articles and documents
Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity
Giannessi, Fabio,Pessotto, Pompeo,Tassoni, Emanuela,Chiodi, Piero,Conti, Roberto,De Angelis, Francesco,Dell'Uomo, Natalina,Catini, Roberto,Deias, Roberto,Tinti, Maria Ornella,Carminati, Paolo,Arduini, Arduino
, p. 303 - 309 (2003)
The synthesis and pharmacological activity of reversible CPT I inhibitors as potential antiketotic and antidiabetic drugs are reported. Such inhibitors constitute a series of enantiomerically pure aminocarnitine derivatives having the general formula (CH3)3N+CH2CH(ZR) CH2COO- (with Z = ureido, carbamate, sulfonamide, and sulfamide moieties; R = C7-C14 linear alkyl chains). A primary pharmacological screening based on the evaluation of CPT I activity in intact rat liver (L-CPT I) mitochondria revealed the best activity for the (R) forms of ureidic derivative 17 (ZR = NHCONHR, R = C14), sulfonamidic derivative 7 (ZR = NHSO2R, R = C12), and sulfamidic derivative 9 (ZR = NHSO2NHR, R = C11). The IC50 values are 1.1, 0.7, and 0.8 μM, respectively. For the carbamic derivative 11 (ZR = NHCOOR, R = C8), an IC50 of 9.5 μM was observed. In addition, an extraordinarily high selectivity toward the liver isoform with respect to the heart isoform (muscle-CPT I M-CPT I) was found for the ureidic compound 17 (IC50(M-CPT I) vs IC50(L-CPTI) = 39.4), as well as for other ureidic or carbamic compounds. Diabetic db/db mice treated orally with 17 and 7 for 45 days at a dose of 50 mg/kg twice a day showed a good reduction of serum glucose levels with respect to the untreated db/db mice (p a potential antiketotic and antidiabetic drug.